Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events.

Lingvay, Ildiko; Hansen, Thomas; Macura, Stanislava; Marre, Michel; Nauck, Michael A; de la Rosa, Raymond; Woo, Vincent; Yildirim, Emre; Wilding, John

Lingvay, Ildiko; Hansen, Thomas; Macura, Stanislava; Marre, Michel; Nauck, Michael A; de la Rosa, Raymond; Woo, Vincent; Yildirim, Emre; Wilding, John.

Afiliación

Lingvay I; Department of Internal Medicine/Endocrinology, University of Texas Southwestern Medical Center, Dallas, Texas, USA Ildiko.Lingvay@UTSouthwestern.edu.
Hansen T; Novo Nordisk A/S, Søborg, Denmark.
Macura S; Novo Nordisk A/S, Søborg, Denmark.
Marre M; Clinique Ambroise Paré, Neuilly sur Seine, France.
Nauck MA; UMRS 1138, Metabolic Inflammation in Diabetes and its Complications Cordeliers Research Centre, Paris, France.
de la Rosa R; Diabetes Division, Katholisches Klinikum Bochum, St Josef Hospital, Bochum, Germany.
Woo V; Endocrinology, Millennium Physician Group, Englewood, Florida, USA.
Yildirim E; Endocrinology and Metabolism, University of Manitoba, Winnipeg, Manitoba, Canada.
Wilding J; Novo Nordisk A/S, Søborg, Denmark.

BMJ Open Diabetes Res Care ; 8(2)2020 10.

Article en En | MEDLINE | ID: mdl-33115821

Asunto(s)

Diabetes Mellitus Tipo 2; Receptor del Péptido 1 Similar al Glucagón; Péptidos Similares al Glucagón; Humanos; Hipoglucemiantes; Pérdida de Peso

Palabras clave

body weight; diabetes mellitus; gastrointestinal tract; glucagon-like peptide 1; type 2

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 2 / Receptor del Péptido 1 Similar al Glucagón Idioma: En Revista: BMJ Open Diabetes Res Care Año: 2020 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google